Doximity, Inc. (DOCS): one to watch?

Fundamentally solid and cheap, but growth has genuinely stalled to ~4% — wait for the Aug 6 earnings to confirm it's stabilizing, not still decaying.

👀 WATCH Fundamentals76/100

Down 80% from its all-time high of $102.02 — now $20.49

Why DOCS dropped

The stock's original 2021-2022 collapse was the broad growth-stock/interest-rate selloff, but the more recent slide (its 30-day high was only 13 sessions ago) came from Doximity's May 2026 Q4 report, where the company gave FY2027 revenue guidance of just ~4% growth — far below the Street's ~9% expectation — citing weak pharma digital-ad demand and rising AI investment costs, which sent shares down over 20% in a day.

Fwd P/E 12.9Op margin 21.6%Rev growth 5.1%Debt/equity 1.1%Analyst upside 19.8%

How this scored 76/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 30.4%

✅ Generates cash Free cash flow $255M

✅ Not drowning in debt Debt/equity 1.1% (limit 200%)

✅ Can pay its bills Current ratio 6.1 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 21/25

Operating margin 21.6% 8/9

Net profit margin 30.4% 8/8

Return on equity 19.3% 6/8

Growth Is it getting bigger, or dying? 11/25

Revenue growth 5.1% 3/9

Earnings growth -69.0% 0/8

Expected profit change 62.6% 8/8

Value Is it cheap right now? 19/25

Forward P/E 12.9 8/10

PEG ratio 0.6 8/8

Analyst target upside 19.8% 2/7

Balance sheet Will it survive? 25/25

Debt / equity 1.1% 10/10

Current ratio 6.1 8/8

Free cash flow $255M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for DOCS — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-23. Research only — not financial advice.